Literature DB >> 31248883

Cancer Clinical Investigators Should Converge with Pharmacometricians.

Michael L Maitland1, Roisin E O'Cearbhaill2, Jogarao Gobburu3.   

Abstract

The applied quantitative science pharmacometrics has significantly enhanced cancer therapeutics development. Pharmacometrics is now improving our understanding of complex diagnostics. Through the concept of convergence and methods of quantitative and systems pharmacology, pharmacometrics is poised to interconnect mathematical models of disease and therapy to advance cancer care.See related article by Colomban et al., p. 5342. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2019        PMID： 31248883      PMCID： PMC8121188          DOI： 10.1158/1078-0432.CCR-19-1067

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

1.  Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.

Authors:  Olivier Colomban; Michel Tod; Alexandra Leary; Isabelle Ray-Coquard; Alain Lortholary; Anne Claire Hardy-Bessard; Jacobus Pfisterer; Andreas Du Bois; Christian Kurzeder; Alexander Burges; Julien Péron; Gilles Freyer; Benoit You
Journal:  Clin Cancer Res       Date:  2019-04-01       Impact factor: 12.531

Review 2.  Quantitative disease, drug, and trial models.

Authors:  Jogarao V S Gobburu; Lawrence J Lesko
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

3.  CA 125 kinetics: a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s.

Authors:  R E Buller; S Vasilev; P J DiSaia
Journal:  Am J Obstet Gynecol       Date:  1996-04       Impact factor: 8.661

4.  Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations.

Authors:  Sharon S Hori; Sanjiv S Gambhir
Journal:  Sci Transl Med       Date:  2011-11-16       Impact factor: 17.956

5.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245
  5 in total
  1 in total

1.  Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy.

Authors:  Thomas S C Ng; Huiyu Hu; Stefan Kronister; Chanseo Lee; Ran Li; Luca Gerosa; Sylwia A Stopka; Danielle M Burgenske; Ishaan Khurana; Michael S Regan; Sreeram Vallabhaneni; Niharika Putta; Ella Scott; Dylan Matvey; Anita Giobbie-Hurder; Rainer H Kohler; Jann N Sarkaria; Sareh Parangi; Peter K Sorger; Nathalie Y R Agar; Heather A Jacene; Ryan J Sullivan; Elizabeth Buchbinder; Hannes Mikula; Ralph Weissleder; Miles A Miller
Journal:  Sci Adv       Date:  2022-04-29       Impact factor: 14.957
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.